TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AdAlta Ltd. ( (AU:1AD) ) just unveiled an update.
AdAlta Limited announced that its Annual General Meeting (AGM) will be held on 19 November 2025 as a hybrid event in Melbourne and via Zoom. The meeting will include a business update from CEO Dr. Tim Oldham. The company is strategically positioned to leverage its expertise in cellular immunotherapies to address the underserved solid cancer market, with its innovative products like AD-214 for fibrotic diseases showing promising results in clinical studies. This positions AdAlta to potentially dominate a high-growth market segment.
More about AdAlta Ltd.
AdAlta Limited is a clinical stage biotechnology company focused on developing effective cellular immunotherapies for the treatment of solid cancers. The company integrates Asian T cell therapy innovations with Australia’s clinical and manufacturing capabilities, aiming to connect these innovations with Western regulated markets. AdAlta employs a capital-efficient business model to deliver rapid returns on investment, with a focus on highly differentiated T cell therapy products for solid cancers, a segment projected to grow significantly.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.38M
See more insights into 1AD stock on TipRanks’ Stock Analysis page.